SNRI-TeCA-Lithium Composition for Treatment Resistant Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for treatment-resistant depression are often ineffective, with only about 25% of patients responding to first-line antidepressant treatments, and existing augmentation strategies have limitations due to side effects and unclear efficacy comparisons.
Innovation Solution
A composition combining a serotonin and norepinephrine reuptake inhibitor (SNRI) like venlafaxine, a tetracyclic antidepressant (TeCA) like mirtazapine, and a mood stabilizer like lithium, administered in a single dosage form to enhance treatment efficacy and reduce suicidal ideation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-line antidepressant treatments are used, then treatment is initiated, but only about 25% of patients achieve adequate response
Solution Approach 1:
The patent combines multiple antidepressant mechanisms (SNRI venlafaxine, TeCA mirtazapine, and mood stabilizer lithium) into a single composite treatment formulation. This merging of different pharmacological classes aims to achieve synergistic effects that improve treatment response rates beyond what single-agent treatments can achieve, directly addressing the low 25% response rate of first-line treatments.
Solution Approach 2:
The treatment composition is designed as a composite pharmacological formulation containing multiple active ingredients with different mechanisms of action. This composite approach allows the treatment to address multiple pathways involved in depression simultaneously, improving reliability of treatment response while maintaining adaptability through a standardized multi-component formulation.
2Adaptability or versatility
If augmentation strategies with multiple medications are used, then treatment options increase, but side effects and complexity increase
Solution Approach 1:
The patent merges multiple medication classes (SNRI, TeCA, and mood stabilizer) into a single integrated treatment composition. This consolidation reduces the complexity of managing multiple separate medications and their associated side effects, while still providing the adaptability and versatility of multi-mechanism treatment. The combined formulation aims to achieve synergistic benefits with reduced overall toxicity compared to separate augmentation strategies.
3Reliability
If multiple separate medications are administered, then treatment coverage is comprehensive, but ease of operation decreases
Solution Approach 1:
The patent combines multiple antidepressant and mood stabilizing agents into a single oral composition that can be administered as one dose. This merging maintains comprehensive treatment coverage by incorporating multiple mechanisms of action (SNRI, TeCA, and lithium) while significantly improving ease of operation compared to managing multiple separate medications. The single-formulation approach simplifies patient compliance and clinical administration while preserving the comprehensive therapeutic coverage needed for treatment-resistant depression.
Data Source
AI summary
A composition for the treatment of treatment resistant depression may include a serotonin and norepinephrine reuptake inhibitor (SNRI), such as venlafaxine; a tetracyclic antidepressant (TeCA), such as mirtazapine; and a mood stabilizer, such as lithium. A method of treating treatment resistant depression may include administering, to a patient in need, a therapeutically effective dosage of the composition.